SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc. (Amendment)
$EGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $26.00 → $17.00 | Neutral → Underweight | Piper Sandler |
| 8/9/2023 | $26.00 → $17.00 | Neutral → Underweight | Piper Sandler |
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication. "This strategic divestitu
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were
WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1. Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin
15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously
Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously
RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00
WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the "Annual Meeting") held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 1. Election of Directors Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin
WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has agreed to appoint Abhinav "Abi" Jain as an independent member of its Board of Directors, subject to customary onboarding procedures. Mr. Jain will be a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders and serve on the Board's Compensation Committee and Nominating and Corporate Governance Committee. In connection with Mr. Jain's planned appointment, Eagle entered into a cooperation agreement (the "Agreement") with Nantahala Capital Management, LLC (together with its affiliates, "Nantahala"),
WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were
WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow
WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)